IN THE CLAIMS:

Please cancel claims 1-30 from the application without prejudice.

Claims 1-30 (cancelled)

31. (original) A pharmaceutical dosage form comprising at least about 50 wt% ranolazine and at least one pH dependent binder that inhibits the release of ranolazine from the sustained release dosage form when the sustained release dosage form is subjected to an aqueous environment having a pH of the stomach and that promotes the release of a therapeutic amount of ranolazine in an aqueous solution having a pH above about 4.5.

32. (original) The pharmaceutical dosage form of claim 31 including no more than two tablets per dose.

33. (original) The pharmaceutical dosage form of claim 32 wherein the pharmaceutical dosage form includes from about 50% to about 95% by weight ranolazine.

34. (original) The pharmaceutical dosage form of claim 32 wherein the pharmaceutical dosage form includes from about 70% to about 80% by weight ranolazine.

35. (original) The pharmaceutical dosage form of claim 31 wherein the pH dependent binder is selected from methacrylic acid copolymers, hydroxypropyl cellulose phthalate, hydroxypropyl methycellulose phthalate, cellulose acetate phthalate, polyvinyl acetate, phthalate, polyvinylpyrrolidine phthalate, and mixtures thereof.

36. (original) The pharmaceutical dosage form of claim 31 wherein the pH dependent binder is a methacrylic acid copolymer.

37. (original) The pharmaceutical dosage form of claim 36 wherein the methacrylic acid copolymer is methacrylic acid copolymer Type C USP.

38. (original) The pharmaceutical dosage form of claim 36 wherein pharmaceutical dosage form includes from about 5 to about 12 wt% methacrylic acid copolymer Type C USP.

39. (original) The pharmaceutical dosage form of claim 36 wherein the pharmaceutical dosage form includes about 10 wt% methacrylic acid copolymer.

40. (original) The pharmaceutical dosage form of claim 31 wherein the pharmaceutical dosage form includes a pH-independent binder.

41. (original) The pharmaceutical dosage form of claim 40 wherein the pH-independent binder is selected from hydroxypropyl methylcellulose, hydroxypropyl cellulose, poly(meth)acrylate esters, poly-vinylpyrrolidone, and mixtures thereof.

42. (original) The pharmaceutical dosage form of claim 40 wherein the pH-independent binder is hydroxypropyl methylcellulose.

43. (original) The pharmaceutical dosage form of claim 42 wherein the pharmaceutical dosage form includes from about 1 to about 3 wt% hydroxypropyl methylcellulose.

44. (original) The pharmaceutical dosage form of claim 42 wherein the pharmaceutical dosage form includes about 2 wt% hydroxypropyl methylcellulose.

45. (original) The pharmaceutical dosage form of claim 31 wherein the dosage form includes from about 650 to about 850 mg ranolazine.

46. (original) The pharmaceutical dosage form of claim 31 wherein the dosage form includes from about 900 to about 1100 mg ranolazine.

47. (original) The pharmaceutical dosage form of claim 31 wherein the dosage form includes from about 400 to about 600 mg ranolazine.

48. (original) The pharmaceutical dosage form of claim 31 wherein the dosage form includes from about 300 to about 1000 mg ranolazine.

49. (original) The pharmaceutical dosage form of claim 32 wherein the pharmaceutical dosage form is a compressed tablet.

50. (original) A compressed tablet comprising from about 70 to about 80 wt% ranolazine, at least one pH dependent binder selected from methacrylic acid copolymers, hydroxypropyl cellulose phthalate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, polyvinyl acetate, phthalate, polyvinylpyrrolidine phthalate, and mixtures thereof, and at least one pH independent binder wherein the compressed tablet includes from about 350 to about 800 mg ranolazine.